Crossmark

Comparison of Bevacizumab Quantification Results in Plasma of Non-small Cell Lung Cancer Patients Using Bioanalytical Techniques Between LC-MS/MS, ELISA, and Microfluidic-based Immunoassay

Crossref DOI link: https://doi.org/10.1208/s12248-019-0369-z

Published Online: 2019-08-20

Published Print: 2019-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Iwamoto, Noriko

Takanashi, Megumi

Shimada, Takashi

Sasaki, Jiichiro

Hamada, Akinobu
License Information

Text and Data Mining valid from 2019-08-20

Version of Record valid from 2019-08-20
More Information

Article History

Received: 18 June 2019

Accepted: 27 July 2019

First Online: 20 August 2019

Compliance with Ethical Standards

: This study was reviewed and approved by the relevant institutional review boards and signed informed consent was obtained from all patients prior to participation. The procedures were in accordance with the Helsinki Declaration.

Document is current

Any future updates will be listed below